Presentation

Egetis Therapeutics is a Swedish pharmaceutical company focusing rare diseases. The lead program Emcitate is intended for the treatment of a rare but severely life-impairing and life-shortening genetic disease, called MCT8 deficiency. The second program, aladote, is being developed against acute liver failure due to paracetamol poisoning. The third asset, pledOx, stopped under the company’s previous name (PledPharma) is being further developed by the Asian partner Solasia. The firm was founded in 2006 (as PledPharma) and changed its name to Egetis Therapeutics upon the merger with Rare Thyroid Therapeutics in 2020.

Recent highlights
The company successfully completed large phase II trial and released positive long-term (up to 6 years) follow-up data. This study confirmed the positive results of the phase II trial and demonstrated the long-term benefits of Emcitate. However, the second asset, aladote, which finds its use in the acute ward (paracetamol poisoning), has understandably been delayed by the pandemic and has yet to start its pivotal trial.

Outlook
Emcitate is currently in a pivotal phase II/III trial. If progress well, we expect the drug can potentially receive market approvals in US and Europe in 2024.